True North is guided by the needs of patients as we discover life-changing medicines for rare diseases. We combine scientific and clinical expertise in diseases of the Complement system so that we can rapidly develop new drugs for rare diseases with few, if any, treatment options. Our R&D is focused on finding novel drugs for rare diseases in which complement is a key driver of pathogenesis. We concentrate on therapies that can intervene upstream in the Complement system, selectively targeting the pathway underlying the disease.
truenorthrx.com
truenorthrx.com
Location: United States, California, South San Francisco
Employees: 11-50
Total raised: $142M
Founded date: 2013
Investors 2
| Date | Name | Website |
| - | Perceptive... | perceptive... |
| - | New Leaf V... | nlvpartner... |
Funding Rounds 4
| Date | Series | Amount | Investors |
| 18.10.2016 | Series D | $45M | - |
| 03.12.2015 | Series C | $40M | - |
| 07.04.2015 | Series B | $35M | - |
| 17.06.2014 | Series A | $22M | - |
Mentions in press and media 16
| Date | Title | Description |
| 29.12.2016 | Why the complement system is set to shine | Humans also have an innate immune system that, among other things, activates antibodies and tags dubious cells for destruction. It does this through a biological cascade known as the complement system. After a slow start, the race is on to ... |
| 18.10.2016 | True North Therapeutics Closes $45M Series D Financing | True North Therapeutics, a South San Francisco, CA-based clinical stage biotechnology company developing novel products that selectively inhibit the Complement system to treat certain rare diseases, completed a $45m Series D equity financin... |
| 18.10.2016 | Redmile Group Joins $45M Series D For True North Therapeutics | True North Therapeutics, a clinical stage biotechnology company developing novel products that selectively inhibit the Complement system to treat certain rare diseases, announced today that it has completed a $45 million Series D equity fin... |
| 18.10.2016 | True North Therapeutics raises $45M in Series D toward rare drug trials | Rare disease focused and early-stage biotech True North Therapeutics (aka TNT) has raised $45 million in its latest funding round as it gears up for midstage tests for its lead candidate TNT009. This med, which inhibits the complement syste... |
| 03.12.2015 | Daily funding roundup - Dec. 3, 2015 | True North Therapeutics bagged $40M; Allocadia raised $16.5M; Younity received $8M funding Younity, an iOS app for streaming media from your Mac, today announced an $8 million Series A round of funding led by venture capital firm Marker LLC... |
| 03.12.2015 | True North Therapeutics Raises $40M | SOUTH SAN FRANCISCO, CA, True North Therapeutics announced today that it has completed a $40 million Series C equity financing. >> Click here for more funding data on True North Therapeutics >> To export True North Therapeut... |
| 03.12.2015 | True North Therapeutics gets $40M new approach to autoimmune disease | True North is developing antibody drugs that work by inhibiting the complement system to prevent the generation of inflammatory mediators and phagocytic markers. The idea here is to restore immune function so that it doesn’t turn on itself ... |
| 03.12.2015 | True North Therapeutics Completes $40M Series C Equity Financing | True North Therapeutics, a South San Francisco, CA-based biotechnology company developing novel therapies that selectively inhibit the Complement system to treat rare diseases, completed a $40m Series C equity financing. The round was led b... |
| 07.04.2015 | True North Therapeutics Completes $35M Series B Equity Financing | True North Therapeutics, a South San Francisco, California-based biotechnology company developing novel therapies that selectively inhibit the Complement system to treat rare diseases, completed a $35m Series B equity financing. The round w... |
| 07.04.2015 | True North Therapeutics Inks $35M Series B | SOUTH SAN FRANCISCO, CA, Biotechnology company developing novel therapies that selectively inhibit the Complement system to treat rare diseases, announced today that it has completed a $35 million Series B round. >> Click here for ... |
Show more